SI1140168T1 - Vaccination against cancer - Google Patents

Vaccination against cancer

Info

Publication number
SI1140168T1
SI1140168T1 SI200030015T SI200030015T SI1140168T1 SI 1140168 T1 SI1140168 T1 SI 1140168T1 SI 200030015 T SI200030015 T SI 200030015T SI 200030015 T SI200030015 T SI 200030015T SI 1140168 T1 SI1140168 T1 SI 1140168T1
Authority
SI
Slovenia
Prior art keywords
against cancer
vaccination against
prophylactically
medicament
manufacture
Prior art date
Application number
SI200030015T
Other languages
English (en)
Slovenian (sl)
Inventor
Helmut Eckert
Hans Loibner
Original Assignee
Igeneon Krebs-Immuntherapie Forschungs- Und Entwicklungs-Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igeneon Krebs-Immuntherapie Forschungs- Und Entwicklungs-Ag filed Critical Igeneon Krebs-Immuntherapie Forschungs- Und Entwicklungs-Ag
Publication of SI1140168T1 publication Critical patent/SI1140168T1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200030015T 1999-01-13 2000-01-12 Vaccination against cancer SI1140168T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH5199 1999-01-13
EP00906191A EP1140168B1 (de) 1999-01-13 2000-01-12 Verwendung von antikörpern zur vakzinierung gegen krebs
PCT/EP2000/000174 WO2000041722A1 (de) 1999-01-13 2000-01-12 Verwendung von antikörpern zur vakzinierung gegen krebs

Publications (1)

Publication Number Publication Date
SI1140168T1 true SI1140168T1 (en) 2002-10-31

Family

ID=4178206

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200030015T SI1140168T1 (en) 1999-01-13 2000-01-12 Vaccination against cancer
SI200030594T SI1230932T1 (en) 1999-01-13 2000-01-12 Use of antibodies for anticancer vaccination

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200030594T SI1230932T1 (en) 1999-01-13 2000-01-12 Use of antibodies for anticancer vaccination

Country Status (28)

Country Link
US (3) US7691372B2 (es)
EP (2) EP1140168B1 (es)
JP (1) JP4774551B2 (es)
KR (1) KR100771752B1 (es)
CN (1) CN1188169C (es)
AT (2) ATE219687T1 (es)
AU (1) AU768515B2 (es)
CA (1) CA2360382C (es)
CZ (1) CZ302801B6 (es)
DE (2) DE50009240D1 (es)
DK (2) DK1140168T3 (es)
EE (1) EE05474B1 (es)
ES (2) ES2177509T3 (es)
HK (1) HK1044487B (es)
HR (1) HRP20010526A2 (es)
HU (1) HU226150B1 (es)
ID (1) ID30223A (es)
IL (2) IL144265A0 (es)
IS (1) IS5998A (es)
MX (1) MXPA01007148A (es)
NO (1) NO329917B1 (es)
NZ (1) NZ512722A (es)
PL (1) PL201533B1 (es)
PT (2) PT1140168E (es)
SI (2) SI1140168T1 (es)
SK (1) SK286627B6 (es)
TR (1) TR200102034T2 (es)
WO (1) WO2000041722A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2360382C (en) * 1999-01-13 2011-05-24 Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag Use of antibodies for the vaccination against cancer
AT410172B (de) 2000-03-21 2003-02-25 Igeneon Gmbh Verfahren zur herstellung einer vakzineformulierung
AT502293B1 (de) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogener, monoklonaler antikörper
AT500647A1 (de) * 2002-05-21 2006-02-15 Igeneon Krebs Immuntherapie Verwendung eines impfstoffes
AT500650B1 (de) 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
AT500651B9 (de) * 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
AU2004321433B2 (en) 2004-07-14 2011-07-21 Greenovation Biotech Gmbh N-glycosylated antibody
ATE483473T1 (de) * 2004-07-20 2010-10-15 Altropus Gmbh Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs
KR101205064B1 (ko) * 2005-04-26 2012-11-27 에자이 알앤드디 매니지먼트 가부시키가이샤 암 면역요법을 위한 조성물과 방법
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
AT504231A1 (de) 2006-10-03 2008-04-15 Hans Dr Loibner Prädiktive parameter
US9119414B2 (en) 2007-12-07 2015-09-01 N.V. Nutricia Bifidobacterium for dust mite allergy
MX2011007049A (es) 2009-02-24 2011-08-03 Esbatech Alcon Biomed Res Unit Metodos para identificar inmunoligadores de los antegenos de la superficie celular.
US8887373B2 (en) 2012-02-24 2014-11-18 Covidien Lp Vessel sealing instrument with reduced thermal spread and method of manufacture therefor
US20140276968A1 (en) * 2013-03-14 2014-09-18 Ethicon, Inc. Applicator systems for surgical fasteners
US10196458B2 (en) * 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341281C (en) * 1986-07-09 2001-08-07 Hubert J.P. Schoemaker Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen
US5270202A (en) * 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
WO1997005597A1 (en) * 1995-07-31 1997-02-13 Litton Systems Canada Limited Flat panel pixel array incorporating photoconductive switches
EP0857176A1 (en) * 1995-10-25 1998-08-12 Centocor B.V. HUMAN EPITHELIAL ANTIGEN Ep-CAM DERIVED PEPTIDES AND THEIR USE
US6235280B1 (en) * 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
IL121041A0 (en) * 1997-06-09 1997-11-20 Yeda Res & Dev Immunogenic compositions for induction of anti-tumor immunity
US6274143B1 (en) * 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
CA2328504A1 (en) * 1998-06-15 1999-12-23 Altarex Corp. Immunotherapeutic composition and method for the treatment of prostate cancer
CA2360382C (en) * 1999-01-13 2011-05-24 Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag Use of antibodies for the vaccination against cancer
US6632431B2 (en) * 2000-05-16 2003-10-14 New York University Anti-idiotypic antibody against FimH adhesion of uropathogenic type I-fimbriated Escherichia coli, compositions containing same and method for using same

Also Published As

Publication number Publication date
SK9642001A3 (en) 2002-03-05
TR200102034T2 (tr) 2001-11-21
NO20013093D0 (no) 2001-06-21
AU768515B2 (en) 2003-12-18
ID30223A (id) 2001-11-15
SI1230932T1 (en) 2005-06-30
NZ512722A (en) 2003-07-25
CN1188169C (zh) 2005-02-09
ATE286745T1 (de) 2005-01-15
SK286627B6 (sk) 2009-02-05
JP2002534481A (ja) 2002-10-15
HU226150B1 (en) 2008-05-28
HK1044487B (zh) 2005-09-16
KR100771752B1 (ko) 2007-10-30
HK1044487A1 (en) 2002-10-25
CZ20012581A3 (cs) 2002-01-16
JP4774551B2 (ja) 2011-09-14
PT1230932E (pt) 2005-04-29
EP1230932A2 (de) 2002-08-14
US8444974B2 (en) 2013-05-21
PT1140168E (pt) 2002-11-29
US20100233178A1 (en) 2010-09-16
US20120003232A1 (en) 2012-01-05
EP1140168A1 (de) 2001-10-10
DK1230932T3 (da) 2005-04-25
KR20010101446A (ko) 2001-11-14
NO20013093L (no) 2001-09-10
US20070224202A1 (en) 2007-09-27
WO2000041722A1 (de) 2000-07-20
HRP20010526A2 (en) 2002-08-31
AU2796400A (en) 2000-08-01
DE50009240D1 (de) 2005-02-17
CN1344167A (zh) 2002-04-10
DK1140168T3 (da) 2002-09-30
EE05474B1 (et) 2011-10-17
IS5998A (is) 2001-07-10
IL144265A (en) 2006-08-20
PL201533B1 (pl) 2009-04-30
CA2360382A1 (en) 2000-07-20
ES2177509T3 (es) 2002-12-16
US7691372B2 (en) 2010-04-06
CZ302801B6 (cs) 2011-11-16
CA2360382C (en) 2011-05-24
MXPA01007148A (es) 2002-03-27
PL364747A1 (en) 2004-12-13
EP1140168B1 (de) 2002-06-26
EE200100366A (et) 2002-10-15
ATE219687T1 (de) 2002-07-15
HUP0200527A2 (en) 2002-06-29
DE50000243D1 (de) 2002-08-01
EP1230932B1 (de) 2005-01-12
ES2236375T3 (es) 2005-07-16
IL144265A0 (en) 2002-05-23
EP1230932A3 (de) 2003-11-26
NO329917B1 (no) 2011-01-24

Similar Documents

Publication Publication Date Title
SI1140168T1 (en) Vaccination against cancer
TR200001253T2 (tr) Tümöre özel antijenler
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
AU2002352394A1 (en) Focussed antibody technology
DK1223980T3 (da) Anvendelse af CSF-1-inhibitorer
AU3607301A (en) Gene recombinant antibody and its fragment
NO985464L (no) Konsentrert antistoffpreparat
CY1112753T1 (el) Θεραπευτικη αγωγη καρκινων του ανθρωπινου σωματος με τη χρηση toy ετ743
BR0108471A (pt) Objeto pré-formado para liberar um agente ativo a um paciente, e, processos de formação de um objeto pré-formado para liberar um agente e de liberação de um agente ativo a um paciente
ATE274919T1 (de) Feste dispergierende impfstoffe-zusammensetzung zur oralen verabreichung
DK1699480T3 (da) Allogent terapeutisk tumormiddel
AU2381402A (en) Small acid-soluble spore protein and uses thereof
WO2004106379A8 (en) Immunotherapy of rectal cancer
NZ512850A (en) Treatment of papillomavirus infections
MY143402A (en) Preparations used in the treatment and prophilaxis of mycobacterial infections
AP2003002852A0 (en) Natural antibodies active against HIV virus